HC Wainwright下调了Amryt Pharma（纳斯达克股票代码：AMYT）的股票评级

Amryt Pharma (NASDAQ:AMYT – Get Rating) was downgraded by investment analysts at HC Wainwright from a "buy" rating to a "neutral" rating in a research note issued to investors on Wednesday, The Fly reports.

A number of other equities analysts have also commented on the company. Canaccord Genuity Group reaffirmed a "hold" rating and issued a $17.00 price objective (down from $19.00) on shares of Amryt Pharma in a research note on Tuesday, January 10th. Maxim Group downgraded shares of Amryt Pharma from a "buy" rating to a "hold" rating in a research report on Tuesday, January 10th. Cantor Fitzgerald cut shares of Amryt Pharma from an "overweight" rating to a "neutral" rating and decreased their price objective for the stock from $25.00 to $14.75 in a research report on Tuesday, January 10th. Finally, SVB Leerink lowered shares of Amryt Pharma from an "outperform" rating to a "market perform" rating and dropped their target price for the company from $19.00 to $14.50 in a report on Monday, January 9th. Five investment analysts have rated the stock with a hold rating, Based on data from MarketBeat, Amryt Pharma presently has an average rating of "Hold" and an average price target of $16.88.

Get Amryt Pharma alerts:

Amryt Pharma Trading Up 0.1 %

Shares of NASDAQ AMYT opened at $14.67 on Wednesday. The firm has a 50 day moving average price of $8.52 and a two-hundred day moving average price of $7.72. The stock has a market cap of $938.34 million, a P/E ratio of -244.50 and a beta of 0.27. Amryt Pharma has a 52-week low of $5.61 and a 52-week high of $14.77. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.94 and a current ratio of 1.57.

Amryt Pharma (NASDAQ:AMYT – Get Rating) last issued its quarterly earnings data on Thursday, November 3rd. The company reported ($0.06) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.02). The business had revenue of $61.13 million during the quarter, compared to the consensus estimate of $66.00 million. Amryt Pharma had a positive return on equity of 1.70% and a negative net margin of 8.19%. As a group, equities analysts forecast that Amryt Pharma will post -0.09 EPS for the current year.

Institutional Trading of Amryt Pharma

A number of hedge funds and other institutional investors have recently bought and sold shares of AMYT. Nantahala Capital Management LLC purchased a new position in Amryt Pharma in the 1st quarter valued at approximately $8,862,000. Renaissance Technologies LLC grew its position in shares of Amryt Pharma by 44.1% in the first quarter. Renaissance Technologies LLC now owns 25,800 shares of the company's stock valued at $213,000 after purchasing an additional 7,900 shares in the last quarter. Hsbc Holdings PLC purchased a new stake in Amryt Pharma during the 1st quarter worth about $202,000. Woodline Partners LP lifted its holdings in Amryt Pharma by 262.7% during the 1st quarter. Woodline Partners LP now owns 480,363 shares of the company's stock worth $3,973,000 after purchasing an additional 347,925 shares in the last quarter. Finally, Bank of America Corp DE grew its holdings in Amryt Pharma by 120.2% during the 1st quarter. Bank of America Corp DE now owns 68,779 shares of the company's stock valued at $569,000 after buying an additional 37,542 shares in the last quarter. Institutional investors own 71.31% of the company's stock.

About Amryt Pharma

(Get Rating)

Amryt Pharma plc, a commercial-stage biopharmaceutical company, focuses on acquiring, developing, and commercializing various treatments to help improve the lives of patients with rare and orphan diseases. The company provides metreleptin, an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy; oral octreotide, a long-term maintenance therapy in acromegaly patients; and lomitapide, an adjunct to a low-fat diet and other lipid-lowering medicinal products for adults with the Homozygous familial Hypercholesteraemia.

Featured Articles

• Get a free copy of the StockNews.com research report on Amryt Pharma (AMYT)
• Exxon Mobil Stock: Within Striking Distance Of Buy Point
• High-Dividend-Yielding BHP Sees China Driving '23 Growth
• Is Airbnb Setting Up To Rally 38%, As Analysts Are Forecasting?
• Does a Price Cut for Tesla Vehicles Mean the Same for TSLA Stock?
• Microsoft Layoffs Signal Layoffs for Other Tech Companies?

Receive News & Ratings for Amryt Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amryt Pharma and related companies with MarketBeat.com's FREE daily email newsletter.